Global Microbiome CDMO Market 2026 by Company, Regions, Type and Application, Forecast to 2032
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Classification of Microbiome CDMO by Type
- 1.3.1 Overview: Global Microbiome CDMO Market Size by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 Global Microbiome CDMO Consumption Value Market Share by Type in 2025
- 1.3.3 Microbial CDMO
- 1.3.4 Antibiotic CDMO
- 1.3.5 Phage CDMO
- 1.3.6 Bacteriocins CDMO
- 1.4 Global Microbiome CDMO Market by Application
- 1.4.1 Overview: Global Microbiome CDMO Market Size by Application: 2021 Versus 2025 Versus 2032
- 1.4.2 Vaccine R&D
- 1.4.3 Biopharmaceutical
- 1.4.4 Cell Therapy
- 1.4.5 Others
- 1.5 Global Microbiome CDMO Market Size & Forecast
- 1.6 Global Microbiome CDMO Market Size and Forecast by Region
- 1.6.1 Global Microbiome CDMO Market Size by Region: 2021 VS 2025 VS 2032
- 1.6.2 Global Microbiome CDMO Market Size by Region, (2021-2032)
- 1.6.3 North America Microbiome CDMO Market Size and Prospect (2021-2032)
- 1.6.4 Europe Microbiome CDMO Market Size and Prospect (2021-2032)
- 1.6.5 Asia-Pacific Microbiome CDMO Market Size and Prospect (2021-2032)
- 1.6.6 South America Microbiome CDMO Market Size and Prospect (2021-2032)
- 1.6.7 Middle East & Africa Microbiome CDMO Market Size and Prospect (2021-2032)
2 Company Profiles
- 2.1 Arranta Bio
- 2.1.1 Arranta Bio Details
- 2.1.2 Arranta Bio Major Business
- 2.1.3 Arranta Bio Microbiome CDMO Product and Solutions
- 2.1.4 Arranta Bio Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Arranta Bio Recent Developments and Future Plans
- 2.2 Wacker Chemie AG
- 2.2.1 Wacker Chemie AG Details
- 2.2.2 Wacker Chemie AG Major Business
- 2.2.3 Wacker Chemie AG Microbiome CDMO Product and Solutions
- 2.2.4 Wacker Chemie AG Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.2.5 Wacker Chemie AG Recent Developments and Future Plans
- 2.3 Bactera
- 2.3.1 Bactera Details
- 2.3.2 Bactera Major Business
- 2.3.3 Bactera Microbiome CDMO Product and Solutions
- 2.3.4 Bactera Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.3.5 Bactera Recent Developments and Future Plans
- 2.4 SGS Quay Pharma
- 2.4.1 SGS Quay Pharma Details
- 2.4.2 SGS Quay Pharma Major Business
- 2.4.3 SGS Quay Pharma Microbiome CDMO Product and Solutions
- 2.4.4 SGS Quay Pharma Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.4.5 SGS Quay Pharma Recent Developments and Future Plans
- 2.5 Biose
- 2.5.1 Biose Details
- 2.5.2 Biose Major Business
- 2.5.3 Biose Microbiome CDMO Product and Solutions
- 2.5.4 Biose Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.5.5 Biose Recent Developments and Future Plans
- 2.6 EnteroBiotix
- 2.6.1 EnteroBiotix Details
- 2.6.2 EnteroBiotix Major Business
- 2.6.3 EnteroBiotix Microbiome CDMO Product and Solutions
- 2.6.4 EnteroBiotix Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.6.5 EnteroBiotix Recent Developments and Future Plans
- 2.7 Genome And Company
- 2.7.1 Genome And Company Details
- 2.7.2 Genome And Company Major Business
- 2.7.3 Genome And Company Microbiome CDMO Product and Solutions
- 2.7.4 Genome And Company Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.7.5 Genome And Company Recent Developments and Future Plans
- 2.8 Lallemand Health Solutions
- 2.8.1 Lallemand Health Solutions Details
- 2.8.2 Lallemand Health Solutions Major Business
- 2.8.3 Lallemand Health Solutions Microbiome CDMO Product and Solutions
- 2.8.4 Lallemand Health Solutions Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.8.5 Lallemand Health Solutions Recent Developments and Future Plans
- 2.9 List Bio
- 2.9.1 List Bio Details
- 2.9.2 List Bio Major Business
- 2.9.3 List Bio Microbiome CDMO Product and Solutions
- 2.9.4 List Bio Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.9.5 List Bio Recent Developments and Future Plans
- 2.10 Rise BioServices
- 2.10.1 Rise BioServices Details
- 2.10.2 Rise BioServices Major Business
- 2.10.3 Rise BioServices Microbiome CDMO Product and Solutions
- 2.10.4 Rise BioServices Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.10.5 Rise BioServices Recent Developments and Future Plans
- 2.11 Lonza
- 2.11.1 Lonza Details
- 2.11.2 Lonza Major Business
- 2.11.3 Lonza Microbiome CDMO Product and Solutions
- 2.11.4 Lonza Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.11.5 Lonza Recent Developments and Future Plans
- 2.12 MaaT Pharma
- 2.12.1 MaaT Pharma Details
- 2.12.2 MaaT Pharma Major Business
- 2.12.3 MaaT Pharma Microbiome CDMO Product and Solutions
- 2.12.4 MaaT Pharma Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 MaaT Pharma Recent Developments and Future Plans
- 2.13 NIZO
- 2.13.1 NIZO Details
- 2.13.2 NIZO Major Business
- 2.13.3 NIZO Microbiome CDMO Product and Solutions
- 2.13.4 NIZO Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.13.5 NIZO Recent Developments and Future Plans
- 2.14 Quay Pharmaceuticals
- 2.14.1 Quay Pharmaceuticals Details
- 2.14.2 Quay Pharmaceuticals Major Business
- 2.14.3 Quay Pharmaceuticals Microbiome CDMO Product and Solutions
- 2.14.4 Quay Pharmaceuticals Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.14.5 Quay Pharmaceuticals Recent Developments and Future Plans
- 2.15 Recipharm
- 2.15.1 Recipharm Details
- 2.15.2 Recipharm Major Business
- 2.15.3 Recipharm Microbiome CDMO Product and Solutions
- 2.15.4 Recipharm Microbiome CDMO Revenue, Gross Margin and Market Share (2021-2026)
- 2.15.5 Recipharm Recent Developments and Future Plans
3 Market Competition, by Players
- 3.1 Global Microbiome CDMO Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
- 3.2.1 Market Share of Microbiome CDMO by Company Revenue
- 3.2.2 Top 3 Microbiome CDMO Players Market Share in 2025
- 3.2.3 Top 6 Microbiome CDMO Players Market Share in 2025
- 3.3 Microbiome CDMO Market: Overall Company Footprint Analysis
- 3.3.1 Microbiome CDMO Market: Region Footprint
- 3.3.2 Microbiome CDMO Market: Company Product Type Footprint
- 3.3.3 Microbiome CDMO Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations
4 Market Size Segment by Type
- 4.1 Global Microbiome CDMO Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global Microbiome CDMO Market Forecast by Type (2027-2032)
5 Market Size Segment by Application
- 5.1 Global Microbiome CDMO Consumption Value Market Share by Application (2021-2026)
- 5.2 Global Microbiome CDMO Market Forecast by Application (2027-2032)
6 North America
- 6.1 North America Microbiome CDMO Consumption Value by Type (2021-2032)
- 6.2 North America Microbiome CDMO Market Size by Application (2021-2032)
- 6.3 North America Microbiome CDMO Market Size by Country
- 6.3.1 North America Microbiome CDMO Consumption Value by Country (2021-2032)
- 6.3.2 United States Microbiome CDMO Market Size and Forecast (2021-2032)
- 6.3.3 Canada Microbiome CDMO Market Size and Forecast (2021-2032)
- 6.3.4 Mexico Microbiome CDMO Market Size and Forecast (2021-2032)
7 Europe
- 7.1 Europe Microbiome CDMO Consumption Value by Type (2021-2032)
- 7.2 Europe Microbiome CDMO Consumption Value by Application (2021-2032)
- 7.3 Europe Microbiome CDMO Market Size by Country
- 7.3.1 Europe Microbiome CDMO Consumption Value by Country (2021-2032)
- 7.3.2 Germany Microbiome CDMO Market Size and Forecast (2021-2032)
- 7.3.3 France Microbiome CDMO Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom Microbiome CDMO Market Size and Forecast (2021-2032)
- 7.3.5 Russia Microbiome CDMO Market Size and Forecast (2021-2032)
- 7.3.6 Italy Microbiome CDMO Market Size and Forecast (2021-2032)
8 Asia-Pacific
- 8.1 Asia-Pacific Microbiome CDMO Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific Microbiome CDMO Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific Microbiome CDMO Market Size by Region
- 8.3.1 Asia-Pacific Microbiome CDMO Consumption Value by Region (2021-2032)
- 8.3.2 China Microbiome CDMO Market Size and Forecast (2021-2032)
- 8.3.3 Japan Microbiome CDMO Market Size and Forecast (2021-2032)
- 8.3.4 South Korea Microbiome CDMO Market Size and Forecast (2021-2032)
- 8.3.5 India Microbiome CDMO Market Size and Forecast (2021-2032)
- 8.3.6 Southeast Asia Microbiome CDMO Market Size and Forecast (2021-2032)
- 8.3.7 Australia Microbiome CDMO Market Size and Forecast (2021-2032)
9 South America
- 9.1 South America Microbiome CDMO Consumption Value by Type (2021-2032)
- 9.2 South America Microbiome CDMO Consumption Value by Application (2021-2032)
- 9.3 South America Microbiome CDMO Market Size by Country
- 9.3.1 South America Microbiome CDMO Consumption Value by Country (2021-2032)
- 9.3.2 Brazil Microbiome CDMO Market Size and Forecast (2021-2032)
- 9.3.3 Argentina Microbiome CDMO Market Size and Forecast (2021-2032)
10 Middle East & Africa
- 10.1 Middle East & Africa Microbiome CDMO Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa Microbiome CDMO Consumption Value by Application (2021-2032)
- 10.3 Middle East & Africa Microbiome CDMO Market Size by Country
- 10.3.1 Middle East & Africa Microbiome CDMO Consumption Value by Country (2021-2032)
- 10.3.2 Turkey Microbiome CDMO Market Size and Forecast (2021-2032)
- 10.3.3 Saudi Arabia Microbiome CDMO Market Size and Forecast (2021-2032)
- 10.3.4 UAE Microbiome CDMO Market Size and Forecast (2021-2032)
11 Market Dynamics
- 11.1 Microbiome CDMO Market Drivers
- 11.2 Microbiome CDMO Market Restraints
- 11.3 Microbiome CDMO Trends Analysis
- 11.4 Porters Five Forces Analysis
- 11.4.1 Threat of New Entrants
- 11.4.2 Bargaining Power of Suppliers
- 11.4.3 Bargaining Power of Buyers
- 11.4.4 Threat of Substitutes
- 11.4.5 Competitive Rivalry
12 Industry Chain Analysis
- 12.1 Microbiome CDMO Industry Chain
- 12.2 Microbiome CDMO Upstream Analysis
- 12.3 Microbiome CDMO Midstream Analysis
- 12.4 Microbiome CDMO Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
- 14.1 Methodology
- 14.2 Research Process and Data Source
According to our (Global Info Research) latest study, the global Microbiome CDMO market size was valued at US$ 1744 million in 2025 and is forecast to a readjusted size of US$ 3283 million by 2032 with a CAGR of 9.6% during review period.
Microbiome CDMO (Contract Development and Manufacturing Organization) is an organization that specializes in providing customized manufacturing and development services to biotechnology and pharmaceutical companies. They mainly focus on providing microbiome research with the entire process from samples to commercial products, including microbiome isolation, culture, identification, storage, extraction, preparation and related product development.
With the continuous deepening of microbiome research, more and more companies and research institutions have begun to realize the application potential of microbiome in medicine, agriculture, food and other fields, which has brought huge market demand to the microbiome CDMO industry.
This report is a detailed and comprehensive analysis for global Microbiome CDMO market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Microbiome CDMO market size and forecasts, in consumption value ($ Million), 2021-2032
Global Microbiome CDMO market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
Global Microbiome CDMO market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
Global Microbiome CDMO market shares of main players, in revenue ($ Million), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Microbiome CDMO
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Microbiome CDMO market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Arranta Bio, Wacker Chemie AG, Bactera, SGS Quay Pharma, Biose, EnteroBiotix, Genome And Company, Lallemand Health Solutions, List Bio, Rise BioServices, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market segmentation
Microbiome CDMO market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Microbial CDMO
Antibiotic CDMO
Phage CDMO
Bacteriocins CDMO
Market segment by Application
Vaccine R&D
Biopharmaceutical
Cell Therapy
Others
Market segment by players, this report covers
Arranta Bio
Wacker Chemie AG
Bactera
SGS Quay Pharma
Biose
EnteroBiotix
Genome And Company
Lallemand Health Solutions
List Bio
Rise BioServices
Lonza
MaaT Pharma
NIZO
Quay Pharmaceuticals
Recipharm
Market segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Microbiome CDMO product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Microbiome CDMO, with revenue, gross margin, and global market share of Microbiome CDMO from 2021 to 2026.
Chapter 3, the Microbiome CDMO competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Microbiome CDMO market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Microbiome CDMO.
Chapter 13, to describe Microbiome CDMO research findings and conclusion.